Mereo BioPharma(MREO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 London, November 12, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and ...